Home LiteratureArticle Details
PMID: 11306596 Published · ppublish English Comment Journal Article

More weapons in the arsenal against ischemic retinopathy.

The Journal of clinical investigation ·Vol. 107 ·No. 8 ·2001-04-00 ·Pages 945-6

Keshet E

Abstract

暂无摘要

MeSH Terms
Animals Endothelial Growth Factors/metabolism Humans Infant, Newborn Ischemia/drug therapy,metabolism Lymphokines/metabolism Neovascularization, Pathologic Nitric Oxide Synthase/antagonists & inhibitors,physiology Nitric Oxide Synthase Type II Nitric Oxide Synthase Type III Retinal Diseases/drug therapy,metabolism Retinopathy of Prematurity/drug therapy,metabolism Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors
Chemicals
Endothelial Growth Factors Lymphokines Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors NOS2 protein, human NOS3 protein, human Nitric Oxide Synthase Nitric Oxide Synthase Type II Nitric Oxide Synthase Type III
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Keshet E
Department of Molecular Biology, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel.
References (19)
19 references, click to expand
  1. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.
    Am J Pathol. 1999 Jun;154(6):1743-53 PMID: 10362799
  2. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy.
    Proc Natl Acad Sci U S A. 1996 May 14;93(10):4851-6 PMID: 8643492
  3. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity.
    Invest Ophthalmol Vis Sci. 1996 Feb;37(2):290-9 PMID: 8603833
  4. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.
    Nat Med. 1995 Oct;1(10):1024-8 PMID: 7489357
  5. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.
    J Clin Invest. 1997 Jun 1;99(11):2625-34 PMID: 9169492
  6. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity.
    Nat Med. 1997 Aug;3(8):879-86 PMID: 9256279
  7. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.
    J Clin Invest. 1997 Dec 15;100(12):3131-9 PMID: 9399960
  8. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.
    Am J Physiol. 1998 Mar;274(3 Pt 2):H1054-8 PMID: 9530221
  9. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor.
    Arch Ophthalmol. 1999 Apr;117(4):498-503 PMID: 10206578
  10. Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP.
    Invest Ophthalmol Vis Sci. 1999 May;40(6):1033-9 PMID: 10235536
  11. Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice.
    Invest Ophthalmol Vis Sci. 1999 Jun;40(7):1624-9 PMID: 10359349
  12. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.
    Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9764-9 PMID: 8790405
  13. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1.
    Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2378-88 PMID: 10892887
  14. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice.
    Invest Ophthalmol Vis Sci. 2001 Jan;42(1):222-8 PMID: 11133872
  15. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor.
    Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2593-7 PMID: 11226284
  16. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy.
    J Clin Invest. 2001 Mar;107(6):717-25 PMID: 11254671
  17. Oxygen-induced retinopathy in the mouse.
    Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101-11 PMID: 7507904
  18. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
    N Engl J Med. 1994 Dec 1;331(22):1480-7 PMID: 7526212
  19. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
    Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10457-61 PMID: 7479819
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
DOI
10.1172/JCI12704
Published
2001-04-00
Pages
945-6
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC199562
Subset
IM
Corrections
CommentOn
PMID: 9169492
CommentOn
PMID: 9399960
CommentOn
PMID: 11254671
CommentOn
PMID: 11306600
External Links
PubMed source DOI: 10.1172/JCI12704 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2